Opna Bio LLC

5 clinical trials · Sponsor

Record	Firm	Date
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma (NCT06433947)	Opna Bio LLC	2024-08-22
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT04556617)	Opna Bio LLC	2020-09-21
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer (NCT04493619)	Opna Bio LLC	2020-08-11
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCT03787498)	Opna Bio LLC	2019-03-19

Every clearance here is in the API, with alerts when new ones post.